CHENGDU,
China, May 10, 2024 /CNW/ -- WestGene, a biotech
company dedicated to mRNA technology, announces a historic
milestone with the FDA IND approval of its mRNA therapeutic cancer
vaccine, WGc-043. This landmark achievement marks the world's first
approval of an EB virus-related mRNA therapeutic cancer
vaccine.
Founded by renowned Dr. Yuquan
Wei, Academician of the Chinese Academy of Sciences, and Dr.
Xiangrong Song, WestGene has
become a driving force in mRNA technology research and innovative
drug development. With a relentless pursuit of scientific
excellence, WestGene's latest milestone underscores its commitment
to advancing the frontiers of biomedicine.
The FDA approval of WGc-043 represents a significant advance in
cancer treatment, offering new hope to patients with advanced EB
virus-related cancers. EB virus is highly correlated with more than
ten malignancies, including nasopharyngeal carcinoma (NPC), natural
killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver
cancer, esophageal cancer, breast cancer, cervical cancer, and
autoimmune diseases such as multiple sclerosis and systemic lupus
erythematosus. These are potential indications for WGc-043.
WGc-043 shows promising efficacy, low toxicity, broad
applicability, efficient scalability, and cost effectiveness.
WGc-043 has already completed investigator-initiated trials (IIT)
in NPC and NKTL, demonstrating superior safety and efficacy
compared to other publicly available mRNA therapeutic cancer
vaccines. Once successfully launched, WGc-043 will provide a new
treatment option for patients with advanced EB virus-positive solid
tumors and hematologic malignancies.
As WestGene moves forward, its strategic focus on global
collaboration underscores its vision for commercial expansion and
market penetration. With a diverse pipeline of over 20 mRNA-based
therapeutic products targeting a spectrum of diseases, WestGene is
poised to reshape the biopharmaceutical landscape. WestGene has
made significant breakthroughs in the three key technologies of
mRNA drug development: mRNA sequence design, delivery vectors, and
manufacturing. And the patent for ionizable lipids has been granted
in countries and regions such as China, the United
States and Europe.
The FDA approval of WGc-043 marks a turning point in the fight
against cancers and underscores WestGene's commitment to mRNA
technology. As WestGene continues to push the boundaries of
scientific discovery, its pioneering spirit promises to open new
frontiers in cancer therapy and beyond.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/westgenes-mrna-therapeutic-cancer-vaccine-receives-fda-approval-302142067.html
SOURCE WestGene